Analysts forecast that Qiagen NV (NASDAQ:QGEN) will report $0.24 earnings per share (EPS) for the current quarter, Zacks reports. Three analysts have issued estimates for Qiagen’s earnings, with the lowest EPS estimate coming in at $0.23 and the highest estimate coming in at $0.25. Qiagen posted earnings of $0.22 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 9.1%. The business is scheduled to issue its next quarterly earnings report on Tuesday, May 1st.
On average, analysts expect that Qiagen will report full year earnings of $1.34 per share for the current year, with EPS estimates ranging from $1.32 to $1.38. For the next fiscal year, analysts forecast that the firm will post earnings of $1.52 per share, with EPS estimates ranging from $1.45 to $1.58. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that cover Qiagen.
Several analysts have recently weighed in on QGEN shares. Cowen restated a “hold” rating and set a $33.00 price objective on shares of Qiagen in a research report on Friday, November 3rd. Commerzbank restated a “buy” rating on shares of Qiagen in a research report on Tuesday, November 7th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Qiagen in a research report on Tuesday, November 7th. Deutsche Bank reaffirmed a “buy” rating on shares of Qiagen in a report on Wednesday, November 8th. Finally, TheStreet raised shares of Qiagen from a “c+” rating to a “b+” rating in a report on Tuesday, November 7th. Eight research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $35.33.
Qiagen declared that its Board of Directors has initiated a stock repurchase plan on Wednesday, January 31st that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its stock is undervalued.
A number of institutional investors and hedge funds have recently made changes to their positions in QGEN. Crossmark Global Holdings Inc. acquired a new position in Qiagen in the 3rd quarter valued at $2,617,000. Frontier Capital Management Co. LLC increased its stake in Qiagen by 0.7% in the 3rd quarter. Frontier Capital Management Co. LLC now owns 2,554,021 shares of the company’s stock valued at $80,452,000 after buying an additional 17,946 shares during the period. Stevens Capital Management LP acquired a new position in Qiagen in the 3rd quarter valued at $1,120,000. Sei Investments Co. increased its stake in Qiagen by 37.5% in the 3rd quarter. Sei Investments Co. now owns 242,613 shares of the company’s stock valued at $7,642,000 after buying an additional 66,194 shares during the period. Finally, New York State Common Retirement Fund increased its stake in Qiagen by 1.6% in the 3rd quarter. New York State Common Retirement Fund now owns 501,947 shares of the company’s stock valued at $15,811,000 after buying an additional 8,000 shares during the period. 62.23% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This story was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3228476/analysts-expect-qiagen-nv-qgen-will-post-earnings-of-0-24-per-share.html.
Qiagen Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.